Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Cancer Vaccines01:30

Cancer Vaccines

367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulation of homeostatic cytokine receptors drives prolonged T cell activation following acute SARS-CoV-2 infection in humans.

Nature communications·2025
Same author

Real-time visualization of STAT activation in live cells using genetically encoded biosensors.

Nature chemical biology·2025
Same author

IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation.

Cells·2025
Same author

In vitro and in vivo evaluation of chemically synthesized, receptor-biased interleukin-4 and photocaged variants.

Science advances·2025
Same author

Immune dysregulation in long COVID.

Nature immunology·2024
Same author

Persistent complement dysregulation with signs of thromboinflammation in active Long Covid.

Science (New York, N.Y.)·2024
Same journal

Intranasal Delivery of an RSV A2-Derived Pre-F VLP Vaccine Induces Robust Mucosal and Systemic Immunity Against RSV B Strain Without Enhanced Disease.

Immune network·2026
Same journal

Selective Enrichment of Non-Canonical Vγ9-Jγ2 TRG Clonotypes in Clear Cell Renal Cell Carcinoma With Shorter CDR3 Loops.

Immune network·2026
Same journal

Regulation of T Cell Senescence in Health and Diseases.

Immune network·2026
Same journal

Apoptotic-Cell Accumulation and Mertk Expression Are Linked to Diminished Antiviral CD8<sup>+</sup> T Cell Immunity in Chronic Infections.

Immune network·2026
Same journal

Respiratory Microbiome Remodeling in Aging: Implications for Immunosenescence and Therapeutic Intervention.

Immune network·2026
Same journal

Synergistic Induction of Neutrophilic Inflammatory Programs by <i>Staphylococcus aureus</i> and Cigarette Smoke in Airway Epithelial Cells.

Immune network·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K

Optimising IL-2 for Cancer Immunotherapy.

Jonathan Sprent1,2,3, Onur Boyman4,5

  • 1Immunology Division, Garvan Institute of Medical Research, Darlinghurst 2010, Australia.

Immune Network
|March 8, 2024
PubMed
Summary
This summary is machine-generated.

Interleukin-2 (IL-2) therapy shows promise for cancer immunotherapy by enhancing T-cell function. Modified IL-2 strategies reduce toxicity, improving anti-tumor responses alongside checkpoint blockade.

Keywords:
Cancer immunotherapyIL-2IL-2 therapyT cells

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

738
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Related Experiment Videos

Last Updated: Jul 1, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

738
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Area of Science:

  • Immunology
  • Cancer immunotherapy
  • Molecular biology

Background:

  • T cells are crucial for cancer immunotherapy, with antibody-mediated checkpoint blockade enhancing anti-tumor responses by overcoming T-cell exhaustion.
  • Current checkpoint blockade therapies show limited efficacy across diverse tumor types, necessitating novel strategies to improve tumor immunity.
  • Interleukin-2 (IL-2) is a potent T-cell growth factor, but its therapeutic use in cancer is hampered by high toxicity.

Purpose of the Study:

  • To review the multifaceted interactions of IL-2 with T cells in various physiological and pathological contexts.
  • To explore the potential of modified IL-2 strategies in overcoming current therapeutic limitations.
  • To highlight the synergistic effects of IL-2 with checkpoint blockade for enhanced anti-tumor immunity.

Main Methods:

  • Literature review of existing research on T cell biology, cancer immunotherapy, and IL-2 signaling.
  • Analysis of studies investigating structural and presentation modifications of IL-2.
  • Examination of data on the combined efficacy of IL-2 and checkpoint blockade in preclinical and clinical settings.

Main Results:

  • IL-2 plays a vital role in T cell homeostasis, pathogen response, and anti-tumor immunity.
  • Structural modifications of IL-2 can significantly reduce its toxicity while preserving or enhancing its therapeutic effects.
  • Engineered IL-2 variants demonstrate potent anti-tumor activity, particularly when combined with checkpoint blockade therapies.

Conclusions:

  • Modified IL-2 represents a promising approach to enhance T cell-mediated anti-tumor responses in cancer immunotherapy.
  • The combination of IL-2 therapy with checkpoint blockade offers a synergistic strategy to improve treatment outcomes.
  • Further research into IL-2 biology and its engineered forms is critical for advancing cancer treatment.